Person seated on stage at TechCrunch Disrupt event, speaking with hands gesturing, water bottle nearby.

Science Corporation raises $400 million as its retina device moves ahead and its brain-interface bet gets bigger

Science raised $400 million in brain-tech funding, valuing the startup at $3.5 billion as PRIMA advances and US approval looms.

Updated November 17, 2026 6:25 pm

In short

Science Corporation’s $400 million round values it at $3.5 billion while supporting PRIMA’s expansion into Stargardt disease and a planned U.S. path via the FDA’s Humanitarian Device Exemption.

  • Science Corporation raised $400 million in Series D funding, with a reported post-money valuation of $3.5 billion.
  • The company’s first product, PRIMA, targets vision loss from age-related macular degeneration and is already approved in Europe.
  • Science plans to pursue a US path through the FDA Humanitarian Device Exemption.
  • The startup is also developing a direct brain interface built around cultured neurons and silicon.

Update — November 17, 2026 6:25 pm

Science Corporation says its PRIMA device is now being trialed for Stargardt disease, adding another blindness-causing condition to the retina treatment’s development program.

The company also said it has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to pursue U.S. clearance through the Humanitarian Device Exemption route.

Science Corporation has raised $400 million in Series D funding and is now valued at $3.5 billion, according to TechCrunch, giving the brain-tech startup fresh capital to push its first eye treatment toward wider use while also advancing a longer-term brain-interface program.

The round underscores how investors are still willing to back ambitious neurotechnology companies even as the near-term business rests on a very specific medical device: PRIMA, Science’s first product, which targets vision loss from age-related macular degeneration and is already approved in Europe and sold in Germany.

What the new funding means

The Series D puts Science Corporation in a stronger position to work on two tracks at once. One is practical and near-term: getting PRIMA through more testing and toward a US regulatory path. The other is much more speculative and far longer dated: a direct brain interface built around a bio-hybrid sensor that combines cultured neurons and silicon.

TechCrunch reported the deal on Nov. 17, saying the financing valued Science at $3.5 billion on a post-money basis, based on a person familiar with the transaction. The company was founded in 2021 by Max Hodak, the former president of Neuralink.

For investors, the round signals confidence not only in the existing retina product but also in the larger ambition behind the startup. For patients and clinicians, it suggests Science may have more runway to expand access to a device that is already in the market in Europe and being studied for additional retinal disease.

Why it matters

This funding round matters because it links a commercialized medical product with an unusually ambitious research pipeline. Science is not raising money only on the promise of a future breakthrough; it already has a product on the market, which makes the company less dependent on the long timeline that usually defines brain-interface research.

That matters for three reasons:

  • For patients: PRIMA could eventually reach more people with severe vision loss if the company advances its US regulatory strategy.
  • For investors: the round offers a way to back a company with a nearer-term device business and a longer-shot platform technology in the same portfolio.
  • For the field: it shows that neurotechnology can still attract large rounds when the company can point to a clinical product and a plausible regulatory route.

The funding also highlights the growing importance of the US regulatory pathway Science says it plans to use for PRIMA: the FDA Humanitarian Device Exemption. TechCrunch reported that this route is being considered because advanced macular degeneration in both eyes is rare enough to fit the exemption framework.

How PRIMA fits into the business

PRIMA is the company’s first product and the clearest evidence that Science Corporation has moved beyond pure research. According to TechCrunch, the device targets vision loss caused by age-related macular degeneration, a condition that can lead to severe central vision loss.

The company has already cleared an important commercial hurdle in Europe. PRIMA is approved there and is being sold in Germany, giving Science a real-world setting in which to gather experience while it builds toward broader expansion.

That Europe-to-US path is important because many medical-device companies spend years on trials without a commercial foothold. Science, by contrast, appears to be using Europe as both a market and a proof point while preparing for the more complicated American regulatory process.

TechCrunch also reported that PRIMA is now being tested for Stargardt’s disease, an inherited retinal disorder that can also cause vision loss. At TechCrunch Disrupt, Hodak said the device was being trialed for that condition, giving the company a second retinal indication to explore.

What is the FDA route Science is aiming for?

The company plans to pursue the FDA Humanitarian Device Exemption, or HDE, a pathway for certain devices intended for rare conditions. In this case, Science is relying on the idea that advanced macular degeneration in both eyes is rare enough to qualify.

That strategy is notable because it offers a narrower, potentially more realistic route than a broader device approval. It also reflects the challenge of bringing specialized neuro-ophthalmic technology to the US market, where evidence standards and reimbursement questions can slow even promising devices.

Background: how Science Corporation got here

Science Corporation was founded in 2021 by Max Hodak, who previously served as president of Neuralink. That origin story has helped define the company from the start: it is a brain-tech startup with a founder already known for working at the intersection of neuroscience, devices and high-risk engineering.

The company’s direction, however, is not limited to one sensational thesis about machine-brain communication. It has built a nearer-term product in PRIMA, a retina device focused on a well-defined clinical problem, while keeping a more ambitious brain-interface effort in development.

According to TechCrunch, the long-term aim is a direct brain interface using a bio-hybrid sensor that combines cultured neurons and silicon. That is a very different proposition from the retinal device, and it suggests the startup is trying to bridge today’s medical-device market and tomorrow’s neural hardware research.

The company’s development path also includes early collaboration with Yale neurosurgery professor Murat Günel. TechCrunch said initial human trials of the brain device are being designed with Günel, who said the device could have potential for Parkinson’s disease and other brain injuries or illnesses.

Who backed the round?

TechCrunch reported that the Series D included Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech among the backers. The presence of both health-care and venture names suggests a mix of strategic and financial interest in the company’s roadmap.

While the fact sheet does not break out each investor’s contribution, the list of participants gives a sense of the breadth of support around the round. It also reflects how neurotechnology often attracts capital from investors willing to take a long view on regulatory and scientific risk.

By the numbers

The following table summarizes the key figures tied to the funding and the company’s timeline.

Metric Figure What it refers to
Series D funding $400 million Capital raised by Science Corporation
Post-money valuation $3.5 billion Investor valuation after the round
Founding year 2021 Year Science Corporation was founded
Primary current product PRIMA Retina device targeting age-related macular degeneration
Current market Europe, including Germany Where PRIMA is approved and sold

How does PRIMA differ from the brain-interface plan?

PRIMA is a near-term therapeutic product aimed at vision loss, while the brain-interface work is a long-horizon research program. The difference matters because each line of work faces a different scientific burden, regulatory path and commercial timeline.

In practical terms, PRIMA can help Science establish manufacturing, clinical evidence and market access. The brain-interface project, by contrast, is still at the stage of designing initial human trials, which places it several steps earlier in the development cycle.

That split may be part of the company’s appeal to investors. A commercial or near-commercial device can support credibility and generate momentum, while a more ambitious platform program preserves the upside that comes with a much larger scientific breakthrough.

Still, the gap between the two is wide. A device for retinal disease and a direct brain interface are related only in the broadest sense: both sit inside neurotechnology. Their risks, study designs and likely patients are not the same.

Timeline

Science’s progress can be sketched across a short but active timeline.

Date Milestone Significance
2021 Science Corporation founded by Max Hodak Company begins with a neurotechnology focus
Before Nov. 17, 2026 PRIMA approved in Europe and sold in Germany Device enters a commercial setting
TechCrunch Disrupt Hodak says PRIMA is being trialed for Stargardt’s disease Signals expansion beyond one retinal indication
Nov. 17, 2026 TechCrunch reports the $400 million Series D and $3.5 billion valuation Company secures major new funding

What the Stargardt’s disease trial could mean

PRIMA’s testing for Stargardt’s disease adds another potential use case for the device, but the fact sheet does not provide the size or design of the trial. Even so, the move matters because inherited retinal disorders can create a separate pathway for evidence, expansion and eventual clinical uptake.

For a startup like Science, expanding into a second disease area can help demonstrate versatility. It can also reveal whether the device has enough technical flexibility to work across different types of retinal damage.

At the same time, every added indication raises new questions about enrollment, endpoints and timing. Those details will likely shape whether Science can build a broader eye-disease franchise or remains focused on a narrower patient population.

Why investors may be comfortable with the valuation

A $3.5 billion valuation for a company that began only in 2021 is striking, but the financing makes more sense when viewed through the lens of what Science already has. The company is not simply selling a concept. It has a product, a European commercial presence and a development pipeline that reaches into one of the most ambitious corners of medical technology.

Investors in this round appear to be betting that PRIMA can keep advancing while the brain-interface work matures slowly in the background. That combination may help explain why the company could command a large valuation despite the long and uncertain road ahead for the direct brain device.

It also reflects a broader truth in medtech and neurotech financing: revenue or regulatory progress on one product can make a far more speculative platform feel investable. Science seems to be using that dynamic to its advantage.

What happens next?

The next phase will likely center on regulatory and clinical milestones rather than consumer-facing product launches. The biggest open questions are the same ones TechCrunch identified: when Science files for the FDA Humanitarian Device Exemption, when PRIMA could reach US patients and how the Stargardt’s disease trial develops.

On the brain-interface side, the most important thing to watch is whether Science moves from design work toward initial human trials with Yale’s Murat Günel. The fact sheet says those trials are being designed, which means the project is still in an early phase.

Investors, clinicians and patients will also be watching for more detail on the Series D itself. The reported funding amount and valuation are public, but the breakdown of each investor’s stake or contribution is not.

For now, the most concrete takeaway is that Science has bought itself time and flexibility. The new capital should help the company push a real, already approved device farther into the market while continuing to build a more ambitious brain-technology platform in parallel.

The bigger picture

Science Corporation’s latest funding round is significant not because it promises an immediate scientific leap, but because it links present-day clinical hardware to future-facing neural engineering. That is a difficult balance to strike, and many startups fail to keep both sides moving.

The company now has the resources to try. Whether it can translate that capital into US regulatory progress for PRIMA, broader retinal indications and eventually the first human tests of its brain-interface concept will determine whether this funding round is a stepping stone or a peak.

“it could offer potential treatments for Parkinson’s disease”

Frequently asked questions

What is Science Corporation?

Science Corporation is a brain-tech startup founded in 2021 by former Neuralink president Max Hodak. Its first product, PRIMA, targets vision loss from age-related macular degeneration, and the company is also developing a direct brain interface.

How much did Science Corporation raise?

Science Corporation raised $400 million in Series D funding, according to TechCrunch. The outlet reported that the round valued the company at $3.5 billion on a post-money basis.

What is PRIMA used for?

PRIMA is designed to target vision loss from age-related macular degeneration. TechCrunch reported that it is approved in Europe, sold in Germany and now being tested for Stargardt’s disease.

How does Science plan to get PRIMA into the US market?

Science plans to pursue the FDA Humanitarian Device Exemption. TechCrunch reported the company believes advanced macular degeneration in both eyes is rare enough to fit that pathway for certain devices intended for rare conditions.

What is Science’s longer-term brain project?

Science’s long-term aim is a direct brain interface using a bio-hybrid sensor that combines cultured neurons and silicon. The company is designing initial human trials with Yale neurosurgery professor Murat Günel.

Share this 🚀